Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5879-5890
DOI: 10.1021/acs.molpharmaceut.6c00947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 07.10.2026. Verfasst von James L Wood und 9 weiteren Autor:innen. Beteiligte Einrichtung: Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland4072, Australia. Hauptthemen laut MEDLINE: Nectins, Urinary Bladder Neoplasms, Immunoconjugates, Antigens, Neoplasm. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian Research Council (ARC), Telix, Telix Pharmaceuticals Limited.
Abstract (Originalsprache)
The application of antibody-drug conjugate (ADC) therapies in advanced bladder cancers may be improved through non-invasive molecular imaging and therapy with targeted radiation. Enfortumab and Sacituzumab, the antibody components for the ADCs PADCEV (Nectin-4 targeting) and TRODELVY (TROP2 targeting), were developed as ImmunoPET and radioimmunotherapeutic modalities in a HT1376 xenograft model of advanced bladder cancer. Both immuno-PET agents displayed distinct tumor uptake in vivo, with Sacituzumab showing higher accumulation (% ID/g) compared to Enfortumab, reflecting the higher TROP2 expression in this tumor model over Nectin-4. Further, both [177Lu]Lu-DOTA-Enfortumab and [177Lu]Lu-DOTA-Sacituzumab were effective in reducing the growth of tumors in vivo. The repurposing of well-validated ADC antibodies as theranostic radiopharmaceuticals is a promising approach for alternative or adjuvant therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland4072, Australia.
- ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals, The University of QueenslandBrisbane4072, Australia.
- Telix Pharmaceuticals Limited , North Melbourne, Victoria3051, Australia.
ORCID-Profile: James L Wood, Benedict Lum, Saikat Ghosh, Alexander H Staudacher, Pie Huda, Peter Chandler, Michael Wheatcroft, Kristofer J Thurecht
Förderung
- Australian Research Council (ARC)
- Telix
- Telix Pharmaceuticals Limited
Zitieren
APA
Wood, J. L., Lum, B., Ghosh, S., Staudacher, A. H., Saravanan, H. S. S., Huda, P., Ivashkevich, A., Chandler, P., Wheatcroft, M., & Thurecht, K. J. (2026). Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer. Molecular Pharmaceutics, 23(11), 5879-5890. https://doi.org/10.1021/acs.molpharmaceut.6c00947
Vancouver
Wood JL, Lum B, Ghosh S, Staudacher AH, Saravanan HSS, Huda P, et al. Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer. Molecular Pharmaceutics. 2026;23(11):5879-5890. doi:10.1021/acs.molpharmaceut.6c00947
BibTeX
@article{Wood2026,
author = {Wood, James L and Lum, Benedict and Ghosh, Saikat and Staudacher, Alexander H and Saravanan, Hari Shree Samyuktha and Huda, Pie and Ivashkevich, Alesia and Chandler, Peter and Wheatcroft, Michael and Thurecht, Kristofer J},
title = {Repurposing Antibody-Drug Conjugates for Theranostic Targeting of Nectin-4 and TROP2 in Bladder Cancer},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5879--5890},
doi = {10.1021/acs.molpharmaceut.6c00947}
}
EUVIMED